Letter

Circulating microRNAs: promising breast cancer biomarkers - authors' response

Carina Roth¹, Brigitte Rack², Volkmar Müller³, Wolfgang Janni⁴, Klaus Pantel¹ and Heidi Schwarzenbach^1*

• * Corresponding author: Heidi Schwarzenbach hschwarz@uke.uni-hamburg.de

Author Affiliations

¹ Institute of Tumor Biology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany

² First Department of Obstetrics and Gynecology, Ludwig Maximilians University of Munich, 80539 Munich, Germany

³ Clinic of Gynecology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany

⁴ Clinic of Gynecology, Heinrich Heine University, 40225 Düsseldorf, Germany

For all author emails, please log on.

Breast Cancer Research 2011, 13:403 doi:10.1186/bcr2812

See related research article by Roth et al., http://breast-cancer-research.com/content/12/6/R90 and related letter by Heneghan et al., http://breast-cancer-research.com/content/13/1/402

The electronic version of this article is the complete one and can be found online at: http://breast-cancer-research.com/content/13/1/403

Published:

4 February 2011

© 2011 BioMed Central Ltd

Letter

We thank Heneghan and colleagues for their interest [1] in our article [2].

We do not claim our article to be the first evidence that circulating microRNAs (miRNAs) have potential as breast cancer biomarkers, and we acknowledge that other groups such as theirs are working on this exciting new area (for example, [3]). However, we think that our data on the association with breast tumor progression are novel.

The finding that total RNA levels were higher in M0 patients than in controls and M1 breast cancer patients cannot exclusively reflect the quality of our used RNA extraction technique because the difference in the concentrations was significant, and we used the same technique for all groups. When we quantified the RNA concentrations using the mirVana PARIS kit (Ambion) and the Trizol^® extraction (Invitrogen), we found the RNA amounts differed considerably, but the relative changes in the RNA levels of the different groups showed the same tendency. The fact that whole blood contains higher RNA amounts than serum/plasma is an undisputable matter. However, we intended to measure the amounts of cell-free RNA.

In our article we discussed that the lower total RNA levels in patients with metastatic disease compared to M0 patients might be explained in part by the different tissue sources (for example, primary tumor, circulating tumor cells and mononuclear cells) from which the bulk of RNA in blood may come. The claim that total RNA concentration indicated tumor progression alludes to the higher total RNA levels detected in the more advanced tumor stages within the M0 subgroup.

We selected our miRNA panel from a large number of existing miRNAs because these miRNAs target mRNAs crucial in breast cancer progression (for example, epithelial-mesenchymal transition). Certainly, there are other miRNAs strongly associated with breast cancer.

We agree that the pre-operative analysis of blood should be more informative for cancer detection, whereas the post-operative analysis might be more valuable to estimate tumor progression. Our small pilot study on sera from 10 patients revealed similar levels before and about 4 weeks after surgery (P = 0.375); however, this aspect needs to be revisited with a larger cohort of patients.

Abbreviations

miRNA: microRNA.

Competing interests

The authors declare that they have no competing interests.

References